Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, specialty drug and medical-device maker Angiotech Pharmaceuticals (NASDAQ:ANPI) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Angiotech's business, and see what CAPS investors are saying about the stock right now.

Angiotech facts

Headquarters (founded)

Vancouver, Canada (1989)

Market Cap

$157.3 million

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$294.9 million

Management

Founder/CEO Dr. William Hunter
CFO Thomas Bailey

Compound Annual Revenue Growth (over last five years)

58.1%

Competitors

Abbott Labs (NYSE:ABT)
Johnson & Johnson (NYSE:JNJ)
Novartis (NYSE:NVS)

CAPS Members Bullish on ANPI Also Bullish on

Citigroup (NYSE:C)
Bank of America (NYSE:BAC)

CAPS Members Bearish on ANPI Also Bearish on

Sears Holdings (NASDAQ:SHLD)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS.

Over on CAPS, 234 of the 253 members who have rated Angiotech -- 92% -- believe the stock will outperform the S&P 500 going forward. These bulls include kschmidt65 and All-Star zzlangerhans, who is ranked in the top 1% of our community.

Late last month, kschmidt65 addressed Angiotech's high risk/high reward nature:

They are in the high margin niche medical device equipment area. Insider buying in the last few months. … They have several products. Financing has been tough and they have approval to issue more stock within the next two years.

In an earlier pitch, zzlangerhans echoes that bullish reasoning:

Angiotech survived lows of [$0.10 per share] on viability concerns after taking on enormous debt to buy American Medical. While the soundness of that decision remains questionable, the stock recently brought 25-fold return to those who bought at the low. The share price has now withdrawn substantially from recent highs even as the company is looking more financially stable with improving stent royalty revenues and approval of additional devices. As long as they don't go [bankrupt], they should rise again from here.

What do you think about Angiotech, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick, Novartis is a Global Gains choice, and Sears Holdings is a selection of Inside Value. The Fool's disclosure policy always gets a perfect score.